Tempus AI teams with Genialis to develop RNA-based biomarker algorithms

Tempus AI (TEM), announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types…Tempus multimodal dataset has already proved pivotal in the launch of Genialis krasID, the first commercially available algorithm that stratifies patients who benefit from KRAS inhibition… “We look forward to working with Genialis and demonstrating new ways in which our data can be applied to further a new kind of research, one that embraces the power that RNA-based biomarkers can have on the future of cancer care,” said Kate Sasser, Ph.D., Chief Scientific Officer at Tempus. “Multimodal algorithms, including RNA signatures, are demonstrating rapid advancement in clinical utility for personalized treatment decisions, and we are excited to partner with Genialis to fuel this data-driven precision medicine future with our xR assay and vast multimodal dataset.”